Growth Metrics

Ligand Pharmaceuticals (LGNDZ) Change in Acquisitions & Divestments (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Acquisitions & Divestments for 15 consecutive years, with $121.0 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 177.34% to $121.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.6 million through Dec 2025, up 381.68% year-over-year, with the annual reading at $159.6 million for FY2025, 381.68% up from the prior year.
  • Change in Acquisitions & Divestments hit $121.0 million in Q4 2025 for Ligand Pharmaceuticals, up from -$44.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $177.7 million in Q3 2022 to a low of -$156.4 million in Q4 2024.
  • Historically, Change in Acquisitions & Divestments has averaged $27.1 million across 5 years, with a median of $14.5 million in 2024.
  • Biggest five-year swings in Change in Acquisitions & Divestments: crashed 826.44% in 2023 and later surged 2116.83% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at -$85.4 million in 2021, then surged by 108.21% to $7.0 million in 2022, then plummeted by 826.44% to -$50.9 million in 2023, then tumbled by 207.24% to -$156.4 million in 2024, then soared by 177.34% to $121.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for LGNDZ at $121.0 million in Q4 2025, -$44.6 million in Q3 2025, and $44.8 million in Q2 2025.